Levacetylmethadol (INN), levomethadyl acetate (USAN), OrLAAM (trade name) or levo-α-acetylmethadol (LAAM)[1][2] is a synthetic opioid similar in structure to methadone.

Unlike methadone, which requires daily administration, LAAM is administered two to three times a week.

LAAM was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence.

In 2001, LAAM was removed from the European market due to reports of life-threatening ventricular rhythm disorders.

At present, it is a Schedule II Narcotic controlled substance in the United States with a DEA ACSCN of 9648 and a national aggregate annual manufacturing quota of 4 grams as of 2013.